Jacobs Levy Equity Management’s Nurix Therapeutics NRIX Stock Holding History

Jacobs Levy Equity Management’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.82M	Sell	363,603 -257,217	-41%	-$4.38M	0.03%	334
2026 Q1	$9.62M	Sell	620,820 -114,354	-16%	-$1.9M	0.04%	309
2025 Q4	$13.9M	Buy	735,174 +691,311	+1,576%	+$9.93M	0.05%	262
2025 Q3	$405K	Buy	+43,863	New	+$456K	﹤0.01%	846
2025 Q1	–	Sell	-229,369	Closed	-$4.32M	–	1159
2024 Q4	$4.32M	Buy	+229,369	New	+$5.26M	0.02%	455
2024 Q3	–	Sell	-224,908	Closed	-$4.69M	–	1023
2024 Q2	$4.69M	Sell	224,908 -209,505	-48%	-$3.26M	0.02%	469
2024 Q1	$6.39M	Buy	434,413 +184,086	+74%	+$1.98M	0.03%	378
2023 Q4	$2.58M	Buy	250,327 +3,247	+1%	+$22.3K	0.01%	559
2023 Q3	$1.94M	Buy	247,080 +200,184	+427%	+$1.83M	0.01%	558
2023 Q2	$468K	Sell	46,896 -109,048	-70%	-$1.11M	﹤0.01%	831
2023 Q1	$1.38M	Sell	155,944 -57,137	-27%	-$595K	0.01%	640
2022 Q4	$2.34M	Buy	213,081 +200,230	+1,558%	+$2.41M	0.02%	524
2022 Q3	$167K	Buy	+12,851	New	+$203K	﹤0.01%	945

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jacobs Levy Equity Management's NRIX Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its Nurix Therapeutics (NRIX) stake by 41% in Q2 2026, selling an estimated $4.38M and leaving 363,603 shares worth $8.82M. The position accounts for 0.03% of the portfolio, ranked #334.

Jacobs Levy Equity Management first reported a position in NRIX in Q3 2022 and has held it in 13 quarters since. The position peaked at $13.9M in Q4 2025. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

Jacobs Levy Equity Management held 363,603 shares of Nurix Therapeutics worth $8.82M as of Q2 2026.
Jacobs Levy Equity Management sold 257,217 Nurix Therapeutics shares in Q2 2026, an estimated $4.38M.
Nurix Therapeutics made up 0.03% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #334 holding.
Jacobs Levy Equity Management first reported a position in Nurix Therapeutics in Q3 2022 and has held it in 13 quarters since.
Jacobs Levy Equity Management's Nurix Therapeutics position peaked at $13.9M in Q4 2025.
212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.